G01N 2800/207
Pigmentation disorders
G01N2800/207 (Pigmentation disorders) appears on 16 US grants and 32 published applications in this corpus.
Search patents in G01N- Granted patents
- 16
- Published applications
- 32
- Assignees
- 32
- Inventors
- 53
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 2 |
| 2016 | 0 | 3 |
| 2017 | 0 | 0 |
| 2018 | 1 | 2 |
| 2019 | 1 | 6 |
| 2020 | 3 | 3 |
| 2021 | 2 | 2 |
| 2022 | 0 | 1 |
| 2023 | 3 | 4 |
| 2024 | 0 | 0 |
| 2025 | 2 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Melanogenesis detection method using FAM86A11 Aug 2026US 12,704,520 B2Research & Business Foundation Sungkyunkwan University
- Biomarkers for vitiligo16 Dec 2025US 12,498,382 B2Incyte Corporation
- Enhancing pigmentation in dermoscopy images8 Jul 2025US 12,350,063 B2Canfield Scientific, Incorporated
- Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders16 May 2023US 11,650,214 B2Chu De Nice
- Biomarkers for vitiligo11 Apr 2023US 11,624,751 B2Incyte Corporation
- Methods for the treatment of mitochondrial disease3 Apr 2025US 2025/0109167 A1Stealth BioTherapeutics Inc.
- Methods for the treatment of mitochondrial disease7 Sep 2023US 2023/0279051 A1Stealth BioTherapeutics Inc.
- Biomarkers for vitiligo13 Jul 2023US 2023/0220478 A1Incyte Corporation
- Enhancing pigmentation in dermoscopy images22 Jun 2023US 2023/0190180 A1Canfield Scientific, Incorporated
- Method for diagnosing esthetic degradations of skin5 Jan 2023US 2023/0003740 A1L'oreal
Most cited
By later US patents
- Compositions and methods for treating vitiligo12US 9,943,563 B2Stealth BioTherapeutics Inc. · 2018
- Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation6US 10,793,597 B2Stealth BioTherapeutics Inc. · 2020
- GSK3B and uses thereof in the diagnostic and treatment of hypopigmentation disorders1US 10,632,117 B2Chu De Nice · 2020
- Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders1US 10,983,134 B2Chu De Nice · 2021